JP5288796B2 - 周期的プロゲスチンレジメン及びキット - Google Patents

周期的プロゲスチンレジメン及びキット Download PDF

Info

Publication number
JP5288796B2
JP5288796B2 JP2007520464A JP2007520464A JP5288796B2 JP 5288796 B2 JP5288796 B2 JP 5288796B2 JP 2007520464 A JP2007520464 A JP 2007520464A JP 2007520464 A JP2007520464 A JP 2007520464A JP 5288796 B2 JP5288796 B2 JP 5288796B2
Authority
JP
Japan
Prior art keywords
days
dosage unit
daily dosage
daily
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007520464A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008505909A (ja
JP2008505909A5 (enExample
Inventor
グラッブ，ガーリー，サンダーマン
コンスタンティーヌ，ジンジャー，デイル
Original Assignee
ワイス・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35064935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5288796(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ワイス・エルエルシー filed Critical ワイス・エルエルシー
Publication of JP2008505909A publication Critical patent/JP2008505909A/ja
Publication of JP2008505909A5 publication Critical patent/JP2008505909A5/ja
Application granted granted Critical
Publication of JP5288796B2 publication Critical patent/JP5288796B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2007520464A 2004-07-07 2005-07-06 周期的プロゲスチンレジメン及びキット Expired - Fee Related JP5288796B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58604504P 2004-07-07 2004-07-07
US60/586,045 2004-07-07
PCT/US2005/023955 WO2006014476A1 (en) 2004-07-07 2005-07-06 Cyclic progestin regimens and kits

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012214378A Division JP2013040181A (ja) 2004-07-07 2012-09-27 周期的プロゲスチンレジメン及びキット

Publications (3)

Publication Number Publication Date
JP2008505909A JP2008505909A (ja) 2008-02-28
JP2008505909A5 JP2008505909A5 (enExample) 2008-08-21
JP5288796B2 true JP5288796B2 (ja) 2013-09-11

Family

ID=35064935

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007520464A Expired - Fee Related JP5288796B2 (ja) 2004-07-07 2005-07-06 周期的プロゲスチンレジメン及びキット
JP2012214378A Pending JP2013040181A (ja) 2004-07-07 2012-09-27 周期的プロゲスチンレジメン及びキット

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012214378A Pending JP2013040181A (ja) 2004-07-07 2012-09-27 周期的プロゲスチンレジメン及びキット

Country Status (14)

Country Link
US (3) US20060009428A1 (enExample)
EP (1) EP1773344A1 (enExample)
JP (2) JP5288796B2 (enExample)
CN (2) CN1980676A (enExample)
AR (1) AR049707A1 (enExample)
AU (1) AU2005269938A1 (enExample)
BR (1) BRPI0512991A (enExample)
CA (1) CA2571377C (enExample)
MX (1) MXPA06014579A (enExample)
PA (1) PA8638601A1 (enExample)
PE (1) PE20060378A1 (enExample)
SV (1) SV2006002165A (enExample)
TW (1) TW200603813A (enExample)
WO (1) WO2006014476A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
EP1773344A1 (en) 2004-07-07 2007-04-18 Wyeth a Corporation of the State of Delaware Cyclic progestin regimens and kits
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
ES2340610T3 (es) * 2005-04-28 2010-06-07 Wyeth Llc Composiciones de tanaproget micronizado y procedimientos de preparacion de las mismas.
JP5149160B2 (ja) * 2005-04-28 2013-02-20 ワイス・エルエルシー ミクロ化タナプロゲットおよびこれを含む組成物
DK1874278T3 (da) * 2005-04-28 2009-09-28 Wyeth Corp Sammensætninger indeholdende mikroniseret tanaproget
CN103989687A (zh) * 2005-06-09 2014-08-20 惠氏公司 含有炔雌醇的tanaproget组合物
US10137135B2 (en) 2005-08-15 2018-11-27 Allergan Sales, Llc Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
US20070093548A1 (en) * 2005-10-25 2007-04-26 Wyeth Use of progesterone receptor modulators
DE102006050558B4 (de) 2006-10-26 2009-03-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System enthaltend Norelgestromin zur Kontrazeption und Hormonsubstitution
EA201070715A1 (ru) 2007-12-20 2011-02-28 Тева Вимен'С Хелс, Инк. Режимы дозирования, фармацевтические композиции и упаковки для экстренной контрацепции
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
WO2010042610A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
CA2740005C (en) 2008-10-08 2016-11-01 Agile Therapeutics, Inc. Transdermal delivery
ES2734510T3 (es) 2008-10-08 2019-12-10 Agile Therapeutics Inc Administración transdérmica
EP2410859A4 (en) 2009-03-27 2013-03-13 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION
RU2016101363A (ru) * 2010-02-08 2018-11-21 Прэари Фармасьютикалз, Ллк Способ лечения заболеваний, связанных с глюкокортикоидной нечувствительностью
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
EP2730284A1 (en) * 2012-11-12 2014-05-14 Naari AG Levonorgestrel-only-composition for optimized oral contraception with defined levonorgestrel content, dosage regimen and pharmaceutical preparation
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
CA2989975C (en) * 2015-06-23 2021-10-12 Laboratorios Leon Farma Sa Drospirenone-based contraceptive for a female patient affected with excess weight
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CN107982520A (zh) * 2017-12-25 2018-05-04 上海交通大学医学院附属第九人民医院 外源性MPA与hMG在制备动物模型药物中的应用
US11679114B2 (en) 2021-07-26 2023-06-20 Navad Life Sciences Pte Progestogen-only oral contraception
WO2024218800A1 (en) * 2023-04-21 2024-10-24 Akums Drugs And Pharmaceuticals Limited Vaginal drug delivery system of dydrogesterone

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU581486B2 (en) * 1985-12-30 1989-02-23 Warner-Lambert Company Graduated estrogen contraceptive
FI101601B1 (fi) * 1987-09-24 1998-07-31 Jencap Research Ltd Ehkäisyvalmiste sekä estrogeenin ja progestiinin käyttö ehkäisyvalmisteen valmistusmenetelmässä
DE69729956T2 (de) * 1996-07-26 2004-12-16 Wyeth Orale einstufige empfängnisverhütungsmethode und kombinationspräparat das gestagen und estrogen enthält
WO2001030355A1 (fr) * 1999-10-25 2001-05-03 Laboratoire Theramex Medicament contraceptif a base d'un progestatif et d'un estrogene et son mode de preparation
AU4134599A (en) * 1998-04-07 1999-10-25 Akzo Nobel N.V. Progestogen-only contraceptive kit
JP4958338B2 (ja) * 1999-05-04 2012-06-20 ワイス・エルエルシー プロゲステロン受容体モジュレーターとしてのシクロチオカルバメート誘導体
US6444668B1 (en) * 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
SI20853A (sl) * 1999-08-31 2002-10-31 Jenapharm Gmbh & Co. Kg Mezoprogestini (modulatorji receptorja progesterona) kot sestavina ženskih kontraceptivov
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
MXPA04012420A (es) * 2002-06-25 2005-04-19 Wyeth Corp Derivados de ciclotiocabamativa como moduladores de rp y uso de los mismos para tratamiento de trastornos de la piel.
EP1773344A1 (en) 2004-07-07 2007-04-18 Wyeth a Corporation of the State of Delaware Cyclic progestin regimens and kits
GT200500186A (es) 2004-07-07 2006-03-02 Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
GT200500183A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos

Also Published As

Publication number Publication date
PA8638601A1 (es) 2006-07-03
WO2006014476A1 (en) 2006-02-09
US20140094458A1 (en) 2014-04-03
CN104208067A (zh) 2014-12-17
JP2008505909A (ja) 2008-02-28
US8604027B2 (en) 2013-12-10
AU2005269938A1 (en) 2006-02-09
PE20060378A1 (es) 2006-06-02
EP1773344A1 (en) 2007-04-18
CA2571377A1 (en) 2006-02-09
US20060009428A1 (en) 2006-01-12
CN1980676A (zh) 2007-06-13
CA2571377C (en) 2014-03-25
SV2006002165A (es) 2006-05-09
JP2013040181A (ja) 2013-02-28
TW200603813A (en) 2006-02-01
BRPI0512991A (pt) 2008-04-22
US20100292198A1 (en) 2010-11-18
AR049707A1 (es) 2006-08-30
MXPA06014579A (es) 2007-03-01

Similar Documents

Publication Publication Date Title
JP5288796B2 (ja) 周期的プロゲスチンレジメン及びキット
US11344551B2 (en) Methods of treating heavy menstrual bleeding
Vannuccini et al. Role of medical therapy in the management of uterine adenomyosis
JP5801801B2 (ja) 緊急避妊のための医薬組成物及び処置方法
US20150359802A1 (en) Parenteral pharmaceutical form which releases aromatse inhibitor and gestagens, for the treatment of endometriosis
KR101812160B1 (ko) 연장된 호르몬성 피임제 투약법에서 파탄성 출혈의 관리
CZ211194A3 (en) Kit for oral contraconception and menses control and a pharmaceutical preparation
HU208487B (en) Process for producing composition for inhibiting human ovulation and for preventinvg mammal cancer
WO2014159377A1 (en) Compositions containing tanaproget and natural estrogens
CN101511336A (zh) 口服单相避孕药的新给药方案
ES2295050T3 (es) Mesoprogestinas para el tratamiento y la prevencion de trastornos ginecologicos benignos dependientes de hormonas.
US12478630B2 (en) Method for treating endometriosis and providing effective contraception
AU2011244870B2 (en) Cyclic progestin regimens and kits
HUP0202515A2 (hu) Mezoprogesztogének (progeszteron receptor modulátorok) alkalmazása női fogamzásgátló gyógyszer komponenseként
BR122025016695A2 (pt) Usos de drospirenona, composição farmacêutica e kit de drospirenona
OA21565A (en) Method for treating endometriosis and providing effective contraception.
Ressler et al. Reversible contraception: Does it affect future fertility?

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080701

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080701

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111114

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111222

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120202

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120612

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120910

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120927

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130521

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130604

LAPS Cancellation because of no payment of annual fees